Abstract-Sepsis, a systemic inflammatory response in the presence of an infection, is characterized by overproduction of inflammatory mediators called cytokines. Removal of these cytokines using an extracorporeal hemoadsorption device is a potential therapy for sepsis. We are developing a cytokine adsorption device (CAD) filled with microporous polymer beads and have previously published a mathematical model which predicts the time course of cytokine removal by the device. The goal of this study was to show that the model can experimentally predict the rate of cytokine capture associated with key design and operational parameters of the CAD. We spiked IL-6, IL-10, and TNF into horse serum and perfused it through an appropriately scaled-down CAD and measured the change in concentration of the cytokines over time. These data were fit to the mathematical model to determine a single model parameter, C i , which is only a function of the cytokinepolymer interaction and the cytokine effective diffusion coefficient in the porous matrix. We compared C i values, which by definition should not change between experiments. Our results indicate that the C i value for a specific cytokine was statistically independent of all other parameters in the model, including initial cytokine concentration, flow rate, serum reservoir volume, CAD size, and bead size. Our results also indicate that competitive adsorption of cytokines and other middle-molecular weight proteins, which is neglected in the model, does not affect the rate of removal of a given cytokine. The model of cytokine capture in the CAD developed in this study will be integrated with a systems model of sepsis to simulate the progression of sepsis in humans and to develop a therapeutic CAD design and intervention protocol that improves patient outcomes in sepsis.
INTRODUCTION
Severe sepsis is an acute inflammatory reaction which arises due to the host response to infection, 6 resulting in systemic inflammation and organ failure. Up to 750,000 patients are affected annually in the US alone, and over one-third die as a result. 1 Sepsis is characterized by the redundant release of multiple inflammatory mediators including cytokines into the bloodstream. 7, 12 Increased expression of proinflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-6 (IL-6) and anti-inflammatory cytokines such as interleukin-10 (IL-10) in the circulation is strongly associated with death. 16 Although several drug therapies have been developed for the treatment of sepsis via blockage of one or more mediators, they have been ineffective because they cannot attenuate the entire response. 3, 10, 22 One possible solution that would non-selectively lower the concentration of circulating cytokines is hemofiltration. Hemofiltration, the removal of plasma solutes after convective filtration from whole blood in hollow fibers, has been shown to lower cytokine concentrations in septic patients. 4, 13 Much of the success of using hemofiltration, however, can be attributed to solute adsorption on to the hollow fiber membranes, 14 and therefore new techniques focus on hemoadsorption in addition to filtration.
We are developing a hemoadsorption device consisting of polymer beads packed in a column through which whole blood is directly perfused. This device has been effective in removing TNF, IL-6, and IL-10, and other middle-molecular weight proteins in both in vitro and ex vivo studies. 19, 21 We have also developed a mathematical model 9 which uses a simple analytic expression to predict the removal rate of cytokines by the hemoadsorption device. The rate of removal depends on one unknown parameter,
where K and q i max are the affinity and capacity of the polymer surface for the cytokine in question, respectively, and D i is the effective diffusion coefficient of the cytokine in the pore structure.
The model we have developed, once validated, will enable us to perform simulations of various experimental scenarios. Eventually this model will be combined with a systems model of sepsis in human patients to evaluate the efficacy of the CAD for various cytokine expression profiles. This method of device design will enable us to develop the most efficient device both quickly and without using costly resources such as cytokines and assay kits. In this paper, we experimentally test the validity of our theoretical model of cytokine capture. As part of our validation, we also justify two key assumptions of the model: (1) that the single parameter gamma is independent of the concentration of the cytokine being captured, and (2) that other adsorbing species do not affect capture of a given cytokine. Our results indicate that the theoretical model predicts cytokine removal well in our hemoadsorption device.
THEORETICAL MODEL
We have previously developed a simple mathematical model 9 which uses the following analytic expression to predict the concentration C i of an individual cytokine i over time, t:
where Q is the volumetric flow rate, V r is the blood or serum reservoir volume, m b is the mass of beads in the column, R is the radius of beads in the column, and q is the density of the polymer. The only unknown parameter in the model is C i which is specific to cytokine i and its interaction with the bead pore and outer surfaces. By definition,
where D i represents the diffusion coefficient of cytokine i within the beads, q i max is the maximum capacity of cytokine i per unit mass of each bead, and K i is the affinity constant from the Langmuir equilibrium adsorption isotherm. In the experiments described below, we measure C i for IL-6, IL-10, and TNF and test that its value is independent of all other experimental parameters.
MATERIALS AND METHODS
The cytokine adsorption device (CAD) consists of a cartridge filled with porous polymer beads. The packed bead bed is approximately 1 cm in diameter and 2 cm in length. As the volume of the scaled-down devices is approximately 300 times smaller than a device that may be used clinically, 17 we employed a 3009 scaledown factor for our baseline reservoir volume and flow rate as well. The beads are made up of a polystyrene divinylbenzene (PSDVB) copolymer and covered in a biocompatible polyvinylpyrrolidone (PVP) coating.
General In Vitro Recirculation Experiments
For each recirculation experiment, an unused CAD was packed with fresh polymer and connected in line with a peristaltic pump (Fig. 1) . The inlet and outlet tubing ports were connected to a reservoir containing 8 mL of horse serum or phosphate buffered saline (PBS) spiked with one or more adsorbable proteins. The reservoir fluid was pumped through the CAD at a set flow rate and samples were taken from the reservoir at times t = 0, 15, 30, 60, 90, 120, 180, and 240 min. Samples were stored at À70°C for subsequent assay using enzyme-linked immunosorbent assay (ELISA). Concentrations of IL-6, IL-10, and TNF were determined using BioSource ELISA kits (Invitrogen, USA) according to the instructions of the manufacturer. The concentration of b 2 -microglobulin was measured using a Quantikine IVD ELISA kit (R&D Systems, USA), also according to the instructions of the manufacturer. 
Experimental Validation of Theoretical Model
Three trials of each model validation experiment described below were performed, and all experimental parameters were set at the baseline values shown in Table 1 unless otherwise specified.
In the first set of experiments, we wanted to test whether the model was able to predict changes in cytokine capture rate associated with changes in the model parameters (Eq. 1), including the initial cytokine concentration in the reservoir, perfusion rate through the cartridge, bead mass in the cartridge, and bead size. To test the effect of initial cytokine concentration, we performed experiments of IL-6 removal using a serum reservoir spiked with either 1000 or 5000 pg/mL, with all other parameters at their baseline values as indicated by Table 1 . Typically, cytokine concentrations in septic patients do not exceed 5000 pg/mL. We tested the effect of changes in flow rate by perfusing serum spiked with IL-6 at a flow rate of 0.8 or 0.08 mL/min while keeping all other parameters at their baseline values. We chose to validate the model for a flow rate below the baseline value as opposed to above it because capture of IL-6 falls into an intermediate regime between perfusion and diffusion-limited capture. Capture is more dependent on flow rate at lower perfusion rates whereas at high flow rates, capture becomes entirely diffusion limited and independent of flow rate.
To test the effect of increasing bead mass in the CAD, we measured capture of IL-6 from serum using devices containing either 1.5 or 10 g of the PSDVB beads. In the case of the 10 g device, a reservoir volume of 80 mL and a flow rate of 8.0 mL/min were used in order to accommodate the larger device. Smaller beads were tested because of the advantage they offer due to their greatly increased surface area and the likelihood that such beads would be included in the final device design. We tested the effect of changes to bead size by performing capture of IL-6 using 289.1 lm radius beads and 58.4 lm radius beads in the CADs. All other parameters remained at their baseline values.
In the second series of experiments, we tested whether competitive binding effects arise due to the presence of multiple adsorbing species, including other cytokines and middle-molecular weight molecules that can diffuse into the porous beads. b2-microglobulin (b2-m) was chosen as the additional adsorbing species because it is the most abundant middle-molecular weight protein in blood that adsorbs onto the CytoSorb beads. We examined whether the presence of b2-m affected the capture rate of IL-6. We performed recirculation experiments using IL-6 alone or with an additional 1.5 lg/mL b2-m spiked into a solution of PBS and 50 mg/mL bovine serum albumin (BSA) with all other parameters at baseline. To directly examine interaction effects between key cytokines of interest, we performed simultaneous IL-6, IL-10, and TNF capture from serum with all parameters at their baseline values.
Model Fitting and Statistical Analysis
The concentrations of TNF, IL-6, and IL-10 over time were normalized to the initial concentration of each cytokine. This data was fit to the model by integrating Eq. (1) using Matlab so that the change in the reservoir volume due to sampling could be incorporated. The integration was subject to the constraint that at t = 0 normalized concentration is 1. The integrated value of C i (t) was then fit to the experimental data. The value of C i found to most closely model cytokine removal for each set of data was obtained via nonlinear regression using Matlab. 95% confidence intervals for both C i and initial concentration were determined along with the R 2 value for each fit. The average C i value was calculated for each set (n = 3) of experiments and compared using a student's t-test. Figure 2 compares IL-6 capture experiments using a serum reservoir spiked with either 1000 or 5000 pg/mL. The 2 AEmLAEmin À1 AEg À1 for the low and high concentrations, respectively. There was no significant difference between the average C IL-6 values (p = 0.63). Figure 3 shows the results of IL-6 capture from serum perfused through the CAD at 0.8 or 0.08 mL/ min. C IL-6 for the lower flow rate was 1.77E-4 ± 1.62E-4 cm 2 AEmLAEmin À1 AEg
RESULTS

Varying Model Parameters
average C IL-6 values obtained over three trials were 1.05E-4 ± 2.34E-5 and 1.17E-4 ± 3.58E-5 cm
À1
and was not significantly different from that for the baseline flow rate (1.05E-4 ± 2.34E-5 cm 2 AEmLAEmin À1 AEg À1 , p = 0.49). Figure 4 shows IL-6 capture data from serum obtained using a CAD containing either 1.5 or 10 g of beads. Reservoir volume and flow rate were increased proportionally to the increase in bead mass, just as they would be for a full scale-up of the device for use in a clinical setting. The average C IL-6 for the larger device was 7.14E-5 ± 4.28E-5 cm 2 AEmLAEmin À1 AEg À1 , which is not statistically different compared to the value for the smaller device (1.05E-4 ± 2.34E-5 cm 2 AEmLAEmin À1 AEg À1 , p = 0.39). Capture of IL-6 from serum in CADs packed with either 289.1 or 58.4 lm radius CytoSorb beads is shown in Fig. 5 . The average C IL-6 value was 8.14E-5 ± 5.78E-5 cm 2 AEmLAEmin À1 AEg À1 for the devices packed with the smaller beads; this value was not significantly different from that obtained with the larger beads (1.05E-4 ± 2.34E-5 cm 2 AEmLAEmin À1 AEg
, p = 0.56).
Competitive Adsorption Effects
In Fig. 6 capture results are shown for IL-6 in a solution of PBS (pH 7.4) and BSA alone or with 1.5 lg/mL b2-m. No statistical difference was found between the average C IL-6 values of 9.59E-5 ± 2.11E-5 and 8.75E-5 ± 5.84E-6 cm 2 AEmLAEmin À1 AEg
À1
for the experiments with and without b2-m, respectively (p = 0.29). Figure 6 also shows that despite its relative abundance in the reservoir, b2-m was rapidly removed by the CAD. Cytokine capture experiments were done using serum spiked with TNF, IL-10, and IL-6 alone or in combination (Fig. 7) . The average C i values for each cytokine in the multicomponent solution were statistically the same as those of the corresponding cytokine alone in solution. These C i values are shown in Table 2 
DISCUSSION
Sepsis is a complex disease characterized by overproduction of cytokines. Cytokine removal using hemoadsorption has demonstrated in animal models some potential as a treatment for sepsis. 15, 19 We are developing a cytokine adsorption device (CAD) based on direct blood perfusion through a cartridge containing novel biocompatible, highly adsorbent polymer beads. We previously developed a theoretical model that can be used to predict the time course of removal of cytokines from extracorporeal circulation through the CAD. The primary goal of this study was to demonstrate experimentally that the model can predict the rate of cytokine capture associated with key design variables of the CAD. These include initial cytokine concentration, perfusion rate through the CAD, and the size of the CAD and of its adsorbing beads. Our experiments indicate that over a clinically relevant range of these parameters the single unknown model parameter (C i ), which accounts for the specific interaction of a particular cytokine i with the adsorbent beads, is statistically unaffected by changes in these parameters. The second goal of this study was to demonstrate experimentally that competitive adsorption of solutes, which is neglected in the model, does not affect the rate of removal of a given cytokine. The results indeed indicate that the presence of either multiple cytokines or relatively high concentrations of b2-m had no effect on the capture rate of cytokines.
The development of our simple model of cytokine capture in the CAD was based on a perturbation analysis in which the effects of competitive adsorption of other solutes on cytokine adsorption were predicted to be secondary. We addressed this experimentally in several different ways. First, we compared the removal rates of IL-6, IL-10, and TNF spiked individually into serum to their respective removal rates when spiked collectively into serum. C i values for each of the three cytokines alone in solution were determined to be statistically the same as C i values for each cytokine in the multiple cytokine solution. Cytokine levels, however, are relatively small (~1000 pg/mL) compared to other middle-molecular weight proteins that can be adsorbed within the beads of the CAD. Accordingly, we also investigated whether the removal rate of cytokines could be affected by the presence of b2-microglobulin (b2-m), which is among the most abundant middle-molecular weight proteins (~1.5 lg/mL). 5 We compared removal rate of IL-6 spiked individually into a solution of PBS and BSA to its removal rate spiked together with 1.5 lg/mL b2-m into the same solution. The C IL-6 values in the two solutions were statistically the same. Finally, we can also compare the C IL-6 value for IL-6 spiked in PBS/BSA solution with that for IL-6 spiked in serum, which would specifically account for possible effects of all other serum proteins. C IL-6 for capture of IL-6 from PBS and BSA was, which was not significantly different from that in serum (9.59E-5 cm 2 AEmLAEmin À1 AEg À1 vs. 1.05E-4 cm 2 AEmLAEmin À1 AEg À1 , respectively, see Table 1 ). We chose to validate our mathematical model by fitting values of the cytokine-specific parameter C i to removal rate data and comparing those fit values for changes to other parameters in the model, as discussed above. A more fundamental way to validate the model would be to measure independently the parameters comprising C i , which include D i , the effective cytokine diffusion coefficient within the beads, and K i and q i max , the Langmuir adsorption isotherm parameters. Measurement of these parameters, however, is neither feasible nor practical. Effective diffusion coefficients in polymer matrices are typically measured in a diffusion chamber apparatus in which a cast polymer film separates a solute-containing chamber from an initially solute-free chamber. Our hemoadsorption polymer cannot be cast into films while maintaining the same pore morphology as in bead form. Advanced microscopy techniques based on visualizing diffusion of labeled proteins directly within individual beads 18, 20 do not provide D i independent of the Langmuir adsorption parameters. Obtaining the Langmuir adsorption isotherm in order to determine K i and q i max is not feasible because the amount of cytokine required to reach equilibrium within a measurable amount of bead material is prohibitive.
The model and the experiments did deviate at later time points for the 58.4 lm radius beads but not for the 289.1 lm radius beads. The deviation occurred only after 90% of IL-6 was removed, and the C IL-6 values were statistically the same for both the large and small beads. This discrepancy may be due to diffusion hindrance caused by partial blocking of the bead pores by cytokines which have already adsorbed. If so, the model could use a variable diffusion coefficient that decreases in proportion to the mass of adsorbed cytokine. Several models for a diffusion coefficient decreasing as a function of adsorbed species already exist. 2, 11 While unlikely to be critical for future applications of the model, studies could be done to incorporate and validate a variable diffusivity.
Our cytokine adsorption device contains a biocompatible polymer and is designed for direct whole blood perfusion. We validated our model using human cytokines spiked into horse serum instead of blood. Our model was developed only to predict the removal rate of cytokines from the plasma phase of blood. Other complexities associated with cytokine release and other interactions with cellular components of blood are incorporated in a systems model of cytokine dynamics in sepsis being developed by our colleagues. 8 Once validated, our model does apply to blood flow through the CAD provided the flow rate and volume parameters in the model (Eq. 1) are those associated with plasma flow and plasma volume. We are currently evaluating this by performing cytokine capture experiments using red blood cells suspended in a PBS/BSA solution spiked with cytokines. Horse serum was used rather than human serum to avoid the interactions between cytokines and their soluble receptors, which are also accounted for in the systems model of sepsis. The model of cytokine capture in the CAD developed here will be integrated with the systems model of sepsis to simulate the progression of sepsis in humans and to develop a therapeutic CAD intervention protocol that improves patient outcomes in sepsis.
